Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product ...

Summary by Hastings Tribune
Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million

3 Articles

Hastings TribuneHastings Tribune
Center

Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product ...

Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million

Read Full Article
BenzingaBenzinga
Reposted by
The Manila TimesThe Manila Times
Center

Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance - Day One Biopharmaceutical (NASDAQ:DAWN)

Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate progress and priorities for 2026 during J.P. Morgan Healthcare Conference, January 12th at 5:15 pm PT (8:15 pm ET) BRISBANE, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a b…

·New York, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 67% of the sources are Center
67% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Benzinga broke the news in New York, United States on Sunday, January 11, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Brisbane icon

Brisbane

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal